Sema4D Expression and Secretion Are Increased by HIF-1α and Inhibit Osteogenesis in Bone Metastases of Lung Cancer

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2019 Jan 9

PMID 30617444

Citations 16

Authors

Wu-Gui Chen

Jing Sun

Wei-Wei Shen

Si-Zhen Yang

Ying Zhang

Xu Hu

Hao Qiu

Shang-Cheng Xu

Tong-Wei Chu

Affiliations

Soon will be listed here.

Abstract

Most lung cancer bone metastasis are characterized by osteolytic destruction and osteoblastic activity is significantly decreased, suggesting that hypoxia may play a critical role in the process, but the underlying mechanisms remain unknown. Semaphorin 4D (Sema4D) is a recently discovered osteogenic inhibitory factor that is expressed at high levels in lung cancers. Here, CoCl-induced hypoxia significantly enhanced the inhibitory effect of lung cancer cell conditioned media on osteoblast differentiation by inducing the expression and secretion of Sema4D in a HIF-1α- but not HIF-2α-dependent manner. Moreover, HIF-1α directly regulated Sema4D expression by binding to bases 1171 to 798 in the Sema4D promoter. Furthermore, hypoxia increased Sema4D secretion by upregulating a disintegrin and metalloproteinase 17 (ADAM17) expression in lung cancer in a HIF-1α-dependent manner. In bone metastasis samples from 49 patients with lung cancer, Sema4D and ADAM17 expression significantly correlated with HIF-1α expression and strongly correlated with a poor differentiation status and osteolytic bone destruction. These results provide the first evidence that HIF-1α-induced Sema4D expression and secretion play important roles in lung cancer osteolytic bone metastasis by inhibiting osteoblast differentiation, thereby providing potential strategies for the treatment of bone metastasis via targeting osteoblasts.

Citing Articles

Skeletal interoception and prospective application in biomaterials for bone regeneration.

Bai L, Li J, Li G, Zhou D, Su J, Liu C Bone Res. 2025; 13(1):1.

PMID: 39743568 PMC: 11693760. DOI: 10.1038/s41413-024-00378-w.

PLXNB1/SEMA4D signals mediate interactions between malignant epithelial and immune cells to promote colorectal cancer liver metastasis.

Xuan Z, Zhang Y, Li D, Wang K, Huang P, Shi J J Cell Mol Med. 2024; 28(20):e70142.

PMID: 39443302 PMC: 11499074. DOI: 10.1111/jcmm.70142.

The Bioactive Compounds of and Their Potential Mechanism of Action in Treating Osteoporosis: A Network Pharmacology and Experimental Validation Study.

Dong H, Tang F, Zhao Z, Huang W, Wan X, Hong Z Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931373 PMC: 11206986. DOI: 10.3390/ph17060706.

The emerging role of the semaphorin family in cartilage and osteoarthritis.

Peng W, Chen Q, Zheng F, Xu L, Fang X, Wu Z Histochem Cell Biol. 2024; 162(3):187-202.

PMID: 38849589 DOI: 10.1007/s00418-024-02303-y.

Bone marrow adipocytes and lung cancer bone metastasis: unraveling the role of adipokines in the tumor microenvironment.

Li J, Wu J, Xie Y, Yu X Front Oncol. 2024; 14:1360471.

PMID: 38571500 PMC: 10987778. DOI: 10.3389/fonc.2024.1360471.

References

Chen Y, Zhang L, Pan Y, Ren X, Hao Q . Over-expression of semaphorin4D, hypoxia-inducible factor-1α and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. Int J Mol Sci. 2012; 13(10):13264-74. PMC: 3497325. DOI: 10.3390/ijms131013264. View

Zhang Y, Wei L, Miron R, Shi B, Bian Z . Anabolic bone formation via a site-specific bone-targeting delivery system by interfering with semaphorin 4D expression. J Bone Miner Res. 2014; 30(2):286-96. DOI: 10.1002/jbmr.2322. View

Mou P, Zeng Z, Li Q, Liu X, Xin X, Wannemacher K . Identification of a calmodulin-binding domain in Sema4D that regulates its exodomain shedding in platelets. Blood. 2013; 121(20):4221-30. PMC: 3656454. DOI: 10.1182/blood-2012-11-470609. View

Rzymski T, Petry A, Kracun D, Riess F, Pike L, Harris A . The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress. Oncogene. 2011; 31(31):3621-34. DOI: 10.1038/onc.2011.522. View

Ruan S, Li R, Han Q, Liu J, Li G, Song Y . Expression and clinical significance of Semaphorin4D in non-small cell lung cancer and its impact on malignant behaviors of A549 lung cancer cells. J Huazhong Univ Sci Technolog Med Sci. 2014; 34(4):491-496. DOI: 10.1007/s11596-014-1304-2. View

Gdowski A, Ranjan A, Vishwanatha J . Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res. 2017; 36(1):108. PMC: 5554406. DOI: 10.1186/s13046-017-0578-1. View

Storti P, Bolzoni M, DOnofrio G, Airoldi I, Guasco D, Toscani D . Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia. 2013; 27(8):1697-706. DOI: 10.1038/leu.2013.24. View

Han Y, You X, Xing W, Zhang Z, Zou W . Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. Bone Res. 2018; 6:16. PMC: 5967329. DOI: 10.1038/s41413-018-0019-6. View

Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T . Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 2007; 67(9):4157-63. DOI: 10.1158/0008-5472.CAN-06-2355. View

10.

Johnson R, Schipani E, Giaccia A . HIF targets in bone remodeling and metastatic disease. Pharmacol Ther. 2015; 150:169-77. PMC: 4414805. DOI: 10.1016/j.pharmthera.2015.02.002. View

11.

Xu P, Derynck R . Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol Cell. 2010; 37(4):551-66. PMC: 4240279. DOI: 10.1016/j.molcel.2010.01.034. View

12.

Maleki K, Cornillet M, Bjorkstrom N . Soluble SEMA4D/CD100: A novel immunoregulator in infectious and inflammatory diseases. Clin Immunol. 2016; 163:52-9. DOI: 10.1016/j.clim.2015.12.012. View

13.

Elhabazi A, Delaire S, Bensussan A, Boumsell L, Bismuth G . Biological activity of soluble CD100. I. The extracellular region of CD100 is released from the surface of T lymphocytes by regulated proteolysis. J Immunol. 2001; 166(7):4341-7. DOI: 10.4049/jimmunol.166.7.4341. View

14.

Black R, Rauch C, Kozlosky C, Peschon J, Slack J, Wolfson M . A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997; 385(6618):729-33. DOI: 10.1038/385729a0. View

15.

Zhu L, Bergmeier W, Wu J, Jiang H, Stalker T, Cieslak M . Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci U S A. 2007; 104(5):1621-6. PMC: 1785259. DOI: 10.1073/pnas.0606344104. View

16.

Zhang Y, Wei L, Miron R, Shi B, Bian Z . Bone scaffolds loaded with siRNA-Semaphorin4d for the treatment of osteoporosis related bone defects. Sci Rep. 2016; 6:26925. PMC: 4890584. DOI: 10.1038/srep26925. View

17.

Yoshida Y, Ogata A, Kang S, Ebina K, Shi K, Nojima S . Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications. Arthritis Rheumatol. 2015; 67(6):1481-90. PMC: 5032998. DOI: 10.1002/art.39086. View

18.

Zhou H, Yang Y, Binmadi N, Proia P, Basile J . The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma. Exp Cell Res. 2012; 318(14):1685-98. PMC: 3389129. DOI: 10.1016/j.yexcr.2012.04.019. View

19.

Zhou B, Peyton M, He B, Liu C, Girard L, Caudler E . Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006; 10(1):39-50. PMC: 4451119. DOI: 10.1016/j.ccr.2006.05.024. View

20.

Tang Y, Qu J, Wu J, Liu H, Chu T, Xiao J . Effect of Surgery on Quality of Life of Patients with Spinal Metastasis from Non-Small-Cell Lung Cancer. J Bone Joint Surg Am. 2016; 98(5):396-402. DOI: 10.2106/JBJS.O.00629. View